{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:21Z","timestamp":1791461361873,"version":"4.3.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003837","name":"Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2005]]},"DOI":"10.1016\/j.mehy.2004.09.015","type":"journal-article","created":{"date-parts":[[2004,11,12]],"date-time":"2004-11-12T12:22:52Z","timestamp":1100262172000},"page":"476-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-\u03b3-inducing property"],"prefix":"10.1016","volume":"64","author":[{"given":"S.","family":"Yamagishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2004.09.015_bib1","first-page":"31","article-title":"Management of the metabolic syndrome","volume":"29","author":"Scheen","year":"2004","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.mehy.2004.09.015_bib2","first-page":"801","article-title":"Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities","volume":"5","author":"Khamaisi","year":"2003","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.mehy.2004.09.015_bib3","doi-asserted-by":"crossref","first-page":"H1597","DOI":"10.1152\/ajpheart.00026.2004","article-title":"Insulin resistance and hypertension","volume":"286","author":"Sowers","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.mehy.2004.09.015_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0025-7125(03)00128-7","article-title":"Insulin and insulin resistance: impact on blood pressure and cardiovascular disease","volume":"88","author":"Sowers","year":"2004","journal-title":"Med Clin North A"},{"key":"10.1016\/j.mehy.2004.09.015_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/107424840300800402","article-title":"Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance","volume":"8","author":"Watson","year":"2003","journal-title":"Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.mehy.2004.09.015_bib6","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1016\/S0149-2918(03)90091-9","article-title":"Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence","volume":"25","author":"Ruilope","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.mehy.2004.09.015_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3810\/pgm.2004.08.1569","article-title":"ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects","volume":"116","author":"Silverstein","year":"2004","journal-title":"Postgrad Med"},{"key":"10.1016\/j.mehy.2004.09.015_bib8","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/00004872-200307006-00006","article-title":"Benefits of blood pressure reduction in diabetic patients","volume":"21","author":"Ball","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.mehy.2004.09.015_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00041552-200405000-00010","article-title":"Impact of the renin-angiotensin system on lipid and carbohydrate metabolism","volume":"13","author":"Strazzullo","year":"2004","journal-title":"Curr Opin Nephrolo Hypertens"},{"key":"10.1016\/j.mehy.2004.09.015_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR\u03b3-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2004.09.015_bib11","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-\u03b3 activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2004.09.015_bib12","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.2174\/1381612043383719","article-title":"Pleiotropic actions of PPAR \u03b3 activators thiazolidinediones in cardiovascular diseases","volume":"10","author":"Takano","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2004.09.015_bib13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","article-title":"Peroxisome proliferator-activated receptors and atherogenesis. Regulators of gene expression in vascular cells","volume":"94","author":"Marx","year":"2004","journal-title":"Cir Res"},{"key":"10.1016\/j.mehy.2004.09.015_bib14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1517\/14656566.5.5.1201","article-title":"Challenges in improving prognosis and therapy: the ongoing telmisartan alone and in combination with ramipril global end point trial programme","volume":"5","author":"Zimmermann","year":"2004","journal-title":"Expert Opin Pharmacother"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987704005420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987704005420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T17:59:16Z","timestamp":1759687156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987704005420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005]]}},"alternative-id":["S0306987704005420"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2004.09.015","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2005]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-\u03b3-inducing property","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2004.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}